4.7 Article

CYT387, a potent IKBKE inhibitor, suppresses human glioblastoma progression by activating the Hippo pathway

Journal

JOURNAL OF TRANSLATIONAL MEDICINE
Volume 19, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12967-021-03070-3

Keywords

CYT387; IKBKE; Glioblastoma; Hippo pathway

Funding

  1. National Nature Science Foundation of China [81572490, 81172405]

Ask authors/readers for more resources

Recent studies have shown that the IKBKE inhibitor CYT387 suppresses glioblastoma cell proliferation, migration, invasion and induces cell apoptosis and cell cycle arrest. Additionally, CYT387 activates the Hippo pathway and reduces IKBKE protein expression. Studies have also suggested that CYT387 has potential as a new antiglioblastoma drug, but further research is needed to address its limited ability to penetrate the blood-brain barrier.
Recent studies have showed that IKBKE is overexpressed in several kinds of cancers and that IKBKE-knockdown inhibits tumor progression. In this article, we first verified that two glioblastoma cell lines, U87-MG and LN-229, were sensitive to CYT387 by measuring the half maximal inhibitory concentration (IC50) with a CCK-8 assay and then demonstrated that CYT387, as a potent IKBKE inhibitor, suppressed glioblastoma cell proliferation, migration and invasion. Additionally, CYT387 induced cell apoptosis and arrested the cell cycle at the G2/M checkpoint in vitro. Furthermore, we showed that CYT387 did not simply inhibit IKBKE activity but also decreased IKBKE expression at the protein level rather than at the mRNA level. We discovered that CYT387 restrained malignant tumor progression by activating the Hippo pathway in vitro. By coimmunoprecipitation (co-IP), we showed that IKBKE interacted with TEAD2 and YAP1, thus accelerating TEAD2 and YAP1 transport into the nucleus. In subsequent in vivo experiments, we found that CYT387 inhibited subcutaneous nude mouse tumor growth but had little impact on intracranial orthotopic xenografts, probably due to a limited ability to penetrate the blood-brain barrier (BBB). These results suggest that CYT387 has potential as a new antiglioblastoma drug, but an approach to allow passage through the blood-brain barrier (BBB) is needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available